AusBiotech is proud to be powering Australia’s Cell and Gene Catalyst (the Catalyst) together with Medicines Australia. Through the work of Marguerite Eveans-Galea, the Catalyst Director, strategic partnerships, stakeholder engagement, and impactful events, the Catalyst is accelerating industry progress and aligning efforts to achieve transformative outcomes.
Highlights from the Catalyst’s Impact Report;
Mobilising the ecosystem
The Catalyst is elevating the national profile of Australia’s cell and gene industry by collaborating with two co-leading peak bodies, six industry partners, and 47 experts from 45 leading organisations. Together, they are aligning advocacy efforts and achieving strategic goals across the cell and gene value chain.
Engaging stakeholders
By delivering 5+ conference keynotes, 20+ events and talks, 200+ stakeholder meetings, and securing 11 media mentions, the Catalyst has effectively engaged both national and international audiences while leveraging social media to expand its reach.
Providing strategic advice
Offering evidence-based insights, the Catalyst has contributed to shaping the future of the sector through policy submissions, consultations, and reviews, including the Health Technology Assessment (HTA) Review and the Health Professionals Scope of Practice Review.
Hosting the Cell and Gene Summit
The Catalyst made history by hosting Australia’s first industry-led Cell and Gene Summit during AusBiotech 2024. This event brought together 230+ delegates and 26 experts in market access, manufacturing, commercialisation, and clinical trials to explore opportunities and celebrate the sector’s impact.
These efforts collectively underscore the Catalyst’s pivotal role in shaping the future of Australia’s cell and gene sector, demonstrating the power of partnership and collaboration in positioning Australia as a global leader in cell and gene innovation.
Read the full report here and see how the Catalyst is shaping the future of healthcare in Australia.
